Goal: Principles of Donor selection. Quiz and examples were shown. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou  

Goal: to get an overview of current cellular therapies and learn where we stand. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou

a reent  study publisghed at LEukemia confirms the role of upfront ASCT in MM. Upfornt autolgous is the standrd of care in MM Presenter: Spyridonidis Patriciapnts: all medical staff

The FDA approved tisagenlecleucel (Kymriah) for certain paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL). The cell-based gene therapy is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that...

Combined use of global and targeted analyses allows the cytogenetic classification of 88% of adult patients with Ph-negative BCP-ALL. • In GRAALL trials, t(4;11)/KMT2A-AFF1 and t(v;14q32)/IGH are the two cytogenetic anomalies significantly associated with a worse outcome. Combined use of global and targeted analyses allows the cytogenetic...

We often see such patients and the question is raised whether transplant could help these poatients. A rertrospetive analysis from the Italian transplant centers tries to answer this. There ia an accompayiong editorial on this analysis. Presenter: Spyridonidis participants: all medical staff 

Venetoclax Gets Breakthrough-Therapy Designation for AML At 12-month follow-up, the overall response rate was 44 percent (complete remission, n=4; complete remission without complete marrow recovery, n=4; resistant disease, n=8; death before evaluation, n=2). FDA Approves Combination Daunorubicin and Cytarabine for High-Risk AML The drug was approved based on...

Wediscussed the incidence and diagnosis of IDH mutations in AML. The new approved drug may prove very helpful for these patients Presenter: Spyridonidis Participants: all medical staff   The US Food and Drug Administration (FDA) has approved enasidenib (Idhifa) for the treatment of relapsed or refractory...

Extended analysis of the fiorst randomized ATG trial in BMT. Presenter: Spyridonidis Participants: All medical staff

Excellent paper by John Dicks group published in Nature. The study identifies the reasosn  why some aptrients relapse also amny years after chemothertpay or allogheneic BMT. Presenter: Spyridonidis Participants: All medical staff

An intersting study showed a correaltion between CHIP and atherpscleorosis. We discussed the CHIP. Presenter Spyridonidis Participants: all medical staff

Στα πλαίσια του εκπαιδευτικού προγράμματος, θα γίνει ενημέρωση την Τρίτη 13/6/2017, ώρα 13:30μ.μ. στα γραφεία της ΜΜΜΟ, από εκπρόσωπο της εταιρίας Novartis, για το φάρμακο Μιντοσταυρίνη. Το φάρμακο έχει πάρει έγκριση για εισαγωγή ασθενών στο Ομαδικό Πρόγραμμα Πρώιμης Πρόσβασης από τον ΕΟΦ καθώς  επίσης...

4 cases of CNS lymphjoma and testicular cancer with CNS disease which responded to PD1 blockade. Clinical reports whith mechanistivc insights Presenter : Spyridonidis Participants: All medial staff

A presentation provided by Abbvie describing the mechanism of action of venetoclax. PArticipants: All medical staff

Presnter: Spyridonidis Participants: all medical staff

Presenter: Spyridonidis Participants: all medical staff